[1] Satterwhite CL, Torrone E, Meites E, Dunne EF, Mahajan R, Ocfemia MC, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis. 2013;40:187-193. doi: https://doi.org/10.1097/OLQ.0b013e318286bb53
[2] Zhao YQ, Zhao FH. Multi-center cross-sectional study on type-specific human papillomavirus infection among chinese women. Chinese Journal of Epidemiology|Chin J Epidemiol. 2016;36:1351-1356.
[3] Viera MH, Amini S, Huo R, Konda S, Block S, Berman B. Herpes simplex virus and human papillomavirus genital infections: new and investigational therapeutic options. Int J Dermatol. 2010;49:733-749. doi: https://doi.org/10.1111/j.1365-4632.2009.04375.x
[4] De Sanjose S. Human papillomavirus genotype attribution in invasive cervical cancer : a retrospective cross-sectional worldwide study. Lancet Oncology. 2010;11.
[5] Serrano B, Alemany L, Tous S, Bruni L, Clifford GM, Weiss T, et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infectious Agents & Cancer. 2012;7:38. doi: https://doi.org/10.1186/1750-9378-7-38
[6] Plummer M, Schiffman M, Castle P, Maucort-Boulch D, Wheeler C. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. Journal of Lower Genital Tract Disease. 2008;12:152. doi: https://doi.org/10.1097/01.lgt.0000305247.00437.26
[7] Rodriguez AC, Schiffman M, Herrero R, Wacholder S, Hildesheim A, Castle PE, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. Journal of the National Cancer Institute. 2008;100:513-517. doi: https://doi.org/10.1093/jnci/djn044
[8] Elfgren K, Naucler P, Dillner J. Management of women with human papillomavirus persistence: long-term follow-up of a randomized clinical trial. American Journal of Obstetrics & Gynecology. 2016. doi: https://doi.org/10.1016/j.ajog.2016.10.042
[9] Nayar R, Wilbur DC. The pap test and bethesda 2014. Cancer Cytopathology.59:121-132.
[10] Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain JM, et al. American cancer society, american society for colposcopy and cervical pathology, and american society for clinical pathology screening guidelines for the prevention and early detection of cervical cancer. American Journal of Clinical Pathology. 2012;16:147-172. doi: https://doi.org/10.1097/LGT.0b013e31824ca9d5
[11] Gage JC, Sadorra M, Lamere BJ, Kail R, Aldrich C, Kinney W, et al. Comparison of the cobas human papillomavirus (HPV) test with the hybrid capture 2 and linear array HPV DNA tests. J Clin Microbiol. 2012;50:61-65. doi: https://doi.org/10.1128/jcm.05989-11
[12] Shi HJ, Song HB, Zhao QY, Tao CX, Liu M. Efficacy and safety of combined high-dose interferon and red light therapy for the treatment of human papillomavirus and associated vaginitis and cervicitis: a prospective and randomized clinical study. Medicine. 2018;97:e12398. doi: https://doi.org/10.1097/MD.0000000000012398
[13] Lince-Deroche N, van Rensburg C, Roseleur J, Sanusi B, Phiri J, Michelow P, et al. Costs and cost-effectiveness of LEEP versus cryotherapy for treating cervical dysplasia among HIV-positive women in Johannesburg, South Africa. PloS one. 2018;13:e0203921. doi: https://doi.org/10.1371/journal.pone.0203921
[14] Yang Y, Meng YL, Duan SM, Zhan SB, Guan RL, Yue TF, et al. REBACIN® as a noninvasive clinical intervention for high-risk human papillomavirus persistent infection. Int J Cancer. 2019. doi: https://doi.org/10.1002/ijc.32344
[15] Katundu K, Bateman AC, Pfaendler KS, Mwanahamuntu MH, Kapambwe S, Vermund SH, et al. The effect of cryotherapy on human papillomavirus clearance among HIV-positive women in Lusaka, Zambia. J Low Genit Tract Dis. 2015;19:301-306. doi: https://doi.org/10.1097/LGT.0000000000000131
[16] Gonzalez-Sanchez JL, Martinez-Chequer JC, Hernandez-Celaya ME, Barahona-Bustillos E, Andrade-Manzano AF. Randomized placebo-controlled evaluation of intramuscular interferon beta treatment of recurrent human papillomavirus. Obstet Gynecol. 2001;97:621-624. doi: https://doi.org/10.1016/s0029-7844(00)01201-1
[17] Cheng YX, Jiang JH, Xue X. The influence of recombinant human α-2b interferon capsule for vaginal foams on the negative conversion rate of HPV. Journal of Practical Obstetrics & Gynecology. 2009.
[18] Sun LL, Song ZQ. Analysis of the efficacy of recombinant human α-2b interferon capsule for vaginal foams Progress in Obstetrics and Gynecology. 2010;20:86-87.
[19] Zhong HW, Ling Y, Zhao J. The effect of Xinfuning on HPV infection in female reproductive tract. Strait Pharmaceutical Journal 2012;24:226-227.
[20] Chen R, Feng L. Clinical observation study of Paiteling on high-risk HPV infection clearance of cervical lesions after conization. The Chinese Journal of Human Sexualit. 2019;28:100-102.
[21] Chen XJ, Ye J. ClinicaI research on effect of vaginaI locaI interferon application on cervicaI high risk human papillomavirus infection. Journal of Practical Obstetrics and Gynecology 2016;32:450-452.
[22] Rositch AF, Burke AE, Viscidi RP, Silver MI, Chang K, Gravitt PE. Contributions of recent and past sexual partnerships on incident human papillomavirus detection: acquisition and reactivation in older women. Cancer Res. 2012;72:6183-6190. doi: https://doi.org/10.1158/0008-5472.Can-12-2635
[23] Maglennon GA, Doorbar J. The biology of papillomavirus latency. Open Virol J. 2012;6:190-197. doi: https://doi.org/10.2174/1874357901206010190
[24] Theiler RN, Farr SL, Karon JM, Paramsothy P, Viscidi R, Duerr A, et al. High-risk human papillomavirus reactivation in human immunodeficiency virus-infected women: risk factors for cervical viral shedding. Obstet Gynecol. 2010;115:1150-1158. doi: https://doi.org/10.1097/AOG.0b013e3181e00927
[25] Unnop J, Xavier C, M. GS, Paulo N, Johanna P, Rowena DR-RM, et al. Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study. PloS one. 2013;8:e79260. doi: https://doi.org/10.1371/journal.pone.0079260
[26] Richardson H, Kelsall G, Tellier P, Voyer H, Abrahamowicz M, Ferenczy A, et al. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev. 2003;12:485-490. doi: https://doi.org/10.1007/s00280-003-0578-z
[27] Stewart M. 2012 Updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Journal of Lower Genital Tract Disease. 2013;17:1-27.
[28] Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, et al. Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. J Low Genit Tract Dis. 2013;17:28-35. doi: https://doi.org/10.1097/LGT.0b013e318285423c
[29] Winer RL HJ, Feng Q, O'Reilly S, Kiviat NB, Holmes KK, Koutsky LA. Condom use and the risk of genital human papillomavirus infection in young women. Obstetrics & Gynecology. 2006;108:1293. doi: https://doi.org/10.1097/01.aog.0000245159.52318.a9